Metabolex, Inc. Initiates Phase 2/3 Trial Of Metaglidasen In Patients With Type 2 Diabetes

HAYWARD, Calif. and WASHINGTON, June 10 /PRNewswire/ -- Metabolex, Inc. announced today the initiation of a Phase 2/3 trial of its lead product candidate, metaglidasen, in patients with type 2 diabetes. A novel insulin sensitizer, metaglidasen has been shown in a previously conducted Phase 2 trial in patients with diabetes to be well tolerated and to lower blood glucose, triglycerides and uric acid levels without causing any increase in weight gain or edema, the common side effects of the currently marketed insulin sensitizers from the thiazolidinedione (TZD) class.

Back to news